Singapore markets close in 4 hours 15 minutes
  • Straits Times Index

    3,103.63
    -16.61 (-0.53%)
     
  • Nikkei

    26,332.66
    +178.85 (+0.68%)
     
  • Hang Seng

    21,955.72
    +125.37 (+0.57%)
     
  • FTSE 100

    7,232.65
    +64.00 (+0.89%)
     
  • BTC-USD

    20,222.36
    +1,108.71 (+5.80%)
     
  • CMC Crypto 200

    439.01
    +18.87 (+4.49%)
     
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Gold

    1,811.70
    +10.20 (+0.57%)
     
  • Crude Oil

    110.39
    +1.96 (+1.81%)
     
  • 10-Yr Bond

    2.8890
    -2.8890 (-100.00%)
     
  • FTSE Bursa Malaysia

    1,438.09
    +0.57 (+0.04%)
     
  • Jakarta Composite Index

    6,740.57
    +101.39 (+1.53%)
     
  • PSE Index

    6,267.30
    +83.68 (+1.35%)
     

HeartCare shares crunch while China Telecom jumps on first trading day

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Gina Lee

Investing.com – Shanghai HeartCare Medical Technology Corp Ltd.'s (HK:6609) shares plunged on their first trading day on the Hong Kong Stock Exchange while China Telecom (NYSE:CHA) Corp’s shares surged in its market debut in Shanghai on Friday.

HeartCare Medical’s Hong Kong shares slipped 23.51% to HK$130.8 ($16.81) by 1:26 AM ET (5:26 AM GMT). It comes after healthcare technology platforms need to get approval from the government for the methods of diagnoses, prescriptions and use of medicine to ensure safety, Chinese media said earlier in the day.

Founded in 2016, HeartCare Medical focuses on developing neuro-interventional medical devices, aiming to reduce the mortality rate and improve the prognosis of stroke.

Its product portfolio includes both neuro-interventional and cardiac medical devices, with both commercialized products and product candidates.

It has two core products, including CaptorTM thrombectomy device (Captor) and left atrial appendage (LAA) occlude. Captor is for the treatment of atacute ischemic stroke and has been commercialized in China, while and the LAA occlude is for atrial fibrillation and is in the process of NMPA registration review.

Nearly half of the net proceeds, or around HK$444.2 million, will be used for the R&D, manufacturing, and marketing of its core products. Four of its products have been commercialized. Moving forward, it expects to commercialize up to nine candidates in 2021 and about 10 candidates from 2022 and 2025, including the sirolimus intracranial drug-eluting balloon catheter for intracranial stenosis treatment.

Meanwhile, China’s largest mobile operator China Telecom’s shares surged nearly 44% on Friday. However, its Hong Kong shares (HK:0728) slid 5.12% on Friday.

The IPO comes as China aims to build the world’s largest 5G networks. The company plans to use the proceeds to develop 5G infrastructure and applications and cloud businesses.

Related Articles

HeartCare shares crunch while China Telecom jumps on first trading day

European Stock Futures Largely Lower; U.K. Retail Sales Slump

Texas Supreme Court rejects Governor Abbott's ban on school mask mandates – CNN

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting